Sirna Therapeutics to Webcast Presentation at the Needham & Company Biotechnology and Medical Technology Conference
June 08 2006 - 9:00AM
PR Newswire (US)
SAN FRANCISCO, June 8 /PRNewswire-FirstCall/ -- Sirna Therapeutics,
Inc. ("Sirna") (NASDAQ:RNAI), a leading RNAi therapeutics company,
announced today that J. Michael French, Sirna's Senior Vice
President of Corporate Development, is scheduled to give a company
presentation at the Needham & Company Biotechnology and Medical
Technology Conference on Thursday, June 15, 2006 at 3:00 p.m. EDT
at The New York Palace Hotel in New York City. A live webcast of
the presentation will be available on the Company's corporate web
site at http://www.sirna.com/. Participants are urged to log on to
the web site 15 minutes prior to the scheduled start time to
download and install any necessary audio software. A replay of the
webcast will be available immediately following the event and will
remain accessible for 30 days. About Sirna Therapeutics Sirna
Therapeutics is a clinical-stage biotechnology company developing
RNAi-based therapies for serious diseases and conditions, including
age-related macular degeneration (AMD), hepatitis B and C,
dermatology, asthma, RSV, Huntington's disease, diabetes and
oncology. Sirna Therapeutics completed its Phase 1 clinical trial
for Sirna-027 in AMD in 2005 and with its strategic partner,
Allergan, Inc., will move Sirna-027 into Phase 2 clinical trials in
2006. Sirna has selected a clinical compound for hepatitis C virus,
Sirna-034, which the Company plans to bring into Phase 1 clinical
trials by the end of 2006. Sirna has established an exclusive
multi-year strategic alliance with GlaxoSmithKline for the
development of siRNA compounds for the treatment of respiratory
diseases. Sirna has a leading intellectual property portfolio in
RNAi covering over 250 mammalian gene and viral targets and over
200 issued or pending patents covering other major aspects of RNAi
technology, including the microRNA technology. More information on
Sirna Therapeutics is available on the Company's web site at
http://www.sirna.com/. Safe Harbor Statement Statements in this
press release which are not strictly historical are
"forward-looking" statements which should be considered as subject
to many risks and uncertainties. For example, most drug candidates
do not become approved drugs. Sirna currently does not have any
clinical drug candidates for the treatment of respiratory diseases,
and the development of Sirna-027 and Sirna-034 as well as Sirna's
other programs are still at a relatively early stage. All of these
programs, and Sirna's ability to obtain milestone and royalty
payments for them, are subject to significant risks and unknowns,
are highly contingent upon future successes, and require
significant funding. In addition, patent applications may not
result in issued patents, and issued patents may not be enforceable
or could be invalidated. Other risks and uncertainties include,
among others, Sirna's early stage of development and short
operating history, Sirna's history and expectation of losses and
need to raise capital, Sirna's need to obtain clinical validation
and regulatory approval for Sirna-027, Sirna-034 and Sirna's other
product candidates, any of which could have negative results,
Sirna's need to engage collaborators, Sirna's need to obtain and
protect intellectual property, and the risk of third-party patent
infringement claims. These and additional risk factors are
identified in Sirna's Securities and Exchange Commission filings,
including the Forms 10-K and 10-Q and in other SEC filings. Sirna
undertakes no obligation to revise or update any forward-looking
statements in order to reflect events or circumstances that may
arise after the date of this release. Contacts: Greg Weaver
Francesca DeMartino SVP and Chief Financial Officer The Ruth Group
Sirna Therapeutics, Inc. (646) 536-7024 415-512-7200 DATASOURCE:
Sirna Therapeutics, Inc. CONTACT: Greg Weaver, SVP and Chief
Financial Officer of Sirna Therapeutics, Inc., +1-415-512-7200; or
Francesca DeMartino of The Ruth Group, +1-646-536-7024, , for Sirna
Therapeutics, Inc. Web site: http://www.sirna.com/
Copyright
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From May 2024 to Jun 2024
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From Jun 2023 to Jun 2024